Phase I/II Clinical Trial for CMT4J

• Post author:
• Post published:February 24, 2026
• Post category:

Continue ReadingPhase I/II Clinical Trial for CMT4J

Phase 1B/2A study of the safety and tolerability of human neural stem cells for Huntington’s Disease (REGEN4HD)

• Post author:
• Post published:February 24, 2026
• Post category:

Continue ReadingPhase 1B/2A study of the safety and tolerability of human neural stem cells for Huntington’s Disease (REGEN4HD)

Inhibitory Interneuron Cell Therapy (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Epilepsy

• Post author:
• Post published:February 24, 2026
• Post category:

Continue ReadingInhibitory Interneuron Cell Therapy (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Epilepsy

The UCLA Delayed Immunological Tolerance after Kidney Transplantation Program

• Post author:
• Post published:February 24, 2026
• Post category:

Continue ReadingThe UCLA Delayed Immunological Tolerance after Kidney Transplantation Program

RPESC-RPE-4W Therapy for dry Age-related Macular Degeneration

• Post author:
• Post published:February 24, 2026
• Post category:

Continue ReadingRPESC-RPE-4W Therapy for dry Age-related Macular Degeneration

A phase 1/2 study to evaluate a bispecific CD19/CD20-directed CAR T cell, in refractory lupus nephritis and systemic lupus erythematosus

• Post author:
• Post published:February 24, 2026
• Post category:

Continue ReadingA phase 1/2 study to evaluate a bispecific CD19/CD20-directed CAR T cell, in refractory lupus nephritis and systemic lupus erythematosus

Personalized antisense oligonucleotide therapy for rare pediatric genetic disease: SCN2A

• Post author:
• Post published:February 24, 2026
• Post category:

Continue ReadingPersonalized antisense oligonucleotide therapy for rare pediatric genetic disease: SCN2A

Autologous ARTEMIS® T Cells to Treat Refractory/Relapsed Pediatric Liver Cancer

• Post author:
• Post published:February 24, 2026
• Post category:

Continue ReadingAutologous ARTEMIS® T Cells to Treat Refractory/Relapsed Pediatric Liver Cancer

Reduced intensity conditioning with JSP191 prior to TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic stem cell transplant for Fanconi Anemia patients

• Post author:
• Post published:February 24, 2026
• Post category:

Continue ReadingReduced intensity conditioning with JSP191 prior to TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic stem cell transplant for Fanconi Anemia patients

Sequential same donor αβdepleted-HSCT from an HLA-partially matched donor allowing immunosuppression free kidney transplant

• Post author:
• Post published:February 24, 2026
• Post category:

Continue ReadingSequential same donor αβdepleted-HSCT from an HLA-partially matched donor allowing immunosuppression free kidney transplant